Medical Management of Inflammatory Bowel Disease in the Elderly. Balancing Safety and Efficacy.

Clinics in Geriatric Medicine

Volumn 30, Issue 1, 2014, Pages 67-78

  Ha, Christina Y ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse events; Coordinated care; Infection; Inflammatory bowel disease; Polypharmacy

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; BIOLOGICAL PRODUCT; CALCIUM; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETANERCEPT; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; STEROID; TUMOR NECROSIS FACTOR INHIBITOR; VITAMIN D;

ADVERSE OUTCOME; AGE DISTRIBUTION; AVASCULAR NECROSIS; BONE DENSITOMETRY; BONE MARROW TOXICITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RISK; CATARACTOGENESIS; CLINICAL FEATURE; CLOSTRIDIUM DIFFICILE INFECTION; COMORBIDITY; CONGESTIVE HEART FAILURE; CORTICOSTEROID THERAPY; CROHN DISEASE; DIABETES MELLITUS; DIGESTIVE FUNCTION; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG ABUSE; DRUG EFFICACY; DRUG EXPOSURE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG UTILIZATION; DRUG WITHDRAWAL; EARLY DIAGNOSIS; ELECTROLYTE DISTURBANCE; ENTERITIS; ENZYME INHIBITION; EYE EXAMINATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; GERIATRIC PATIENT; GLAUCOMA; GLOMERULUS FILTRATION RATE; HOSPITALIZATION; HUMAN; HYPERSENSITIVITY; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INDEPENDENT VARIABLE; INFECTION; INFECTION RISK; INTERSTITIAL NEPHRITIS; INTESTINE FLORA; KIDNEY FAILURE; KIDNEY FUNCTION; LEUKOPENIA; LONG TERM CARE; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MALNUTRITION; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OSTEOPOROSIS; PATIENT MONITORING; POLYPHARMACY; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN EXAMINATION; SMOKING; STEROID THERAPY; SUNLIGHT PROTECTION; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADVERSE EVENTS; COORDINATED CARE; INFECTION; INFLAMMATORY BOWEL DISEASE; POLYPHARMACY;

AGED; AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOTRANSFORMATION; COMORBIDITY; COST OF ILLNESS; DRUG INTERACTIONS; DRUG MONITORING; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MEDICATION THERAPY MANAGEMENT; MESALAMINE; POLYPHARMACY; RISK ASSESSMENT;

EID: 84888154953     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.10.007     Document Type: Review

References (68)

1. Khalili H., Huang E.S., Ananthakrishnan A.N., et al. Geographical variation and incidence of inflammatory bowel disease among US women. Gut 2012, 61:1686-1692.
2. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009, 41:67-76.
3. Tinetti M.E., Bogardus S.T., Agostini J.V. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. NEngl J Med 2004, 351:2870-2874.
4. Gurwitz J.H., Field T.S., Harrold L.R., et al. Incidence and preventability of adverse drug events among older persons in the ambulatory setting. JAMA 2003, 289:1107-1116.
5. Qato D.M., Alexander G.C., Conti R.M., et al. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008, 300:2867-2878.
6. Kaufman D.W., Kelly J.P., Rosenberg L., et al. Recent patterns of medication use in the ambulatory adult population of the United States: the Slone survey. JAMA 2002, 287:337-344.
7. Rochon P.A., Gurwitz J.H. Optimising drug treatment for elderly people: the prescribing cascade. BMJ 1997, 315:1096-1099.
8. Pineton de Chambrun G., Peyrin-Biroulet L., Lemann M., et al. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol 2010, 7:15-29.
9. D'Haens G., Baert F., van Assche G., et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371:660-667.
10. Colombel J.F., Sandborn W.J., Reinisch W., et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. NEngl J Med 2010, 362:1383-1395.
11. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
12. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107:1409-1422.
13. Tourner M., Loftus E.V., Harmsen W.S., et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008, 134:929-936.
14. Grijalva C.G., Chen L., Delzell E., et al. Initiation of tumor necrosis factor-alpha antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. JAMA 2011, 306:2331-2339.
15. Ha C.Y., Katz S. Clinical outcomes and management of inflammatory bowel disease in the older patient. Curr Gastroenterol Rep 2013, 15:310-317.
16. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infectious and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006, 4:621-630.
17. Castle S.C. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000, 31:578-585.
18. Pawelec G. Immunosenescence: impact in the young as well as the old?. Mech Ageing Dev 1999, 108:1-7.
19. Cucchiara S., Iebba V., Conte M.P., et al. The microbiota in inflammatory bowel disease in different age groups. Dig Dis 2009, 27:252-258.
20. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008, 57:205-210.
21. Ananthakrishnan A.N., McGinley E.L. Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. JCrohns Colitis 2013, 7:107-112.
22. Katz S., Pardi D.S. Inflammatory bowel disease of the elderly: frequently asked questions (FAQs). Am J Gastroenterol 2011, 106:1889-1897.
23. Lichtenstein G.R., Hanauer S.B., Sandborn W.J. Management of Crohn's disease in adults. Am J Gastroenterol 2009, 104:465-483.
24. Kornbluth A., Sachar D.B. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010, 105:501-523.
25. Ford A.C., Khan K.J., Sandborn W.J., et al. Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011, 106:2070-2077.
26. Kane S.V., Sumner M., Solomon D., et al. Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database. Dig Dis Sci 2011, 56:3463-3470.
27. Kapur K.C., Williams G.T., Allison M.C. Mesalazine induced exacerbation of ulcerative colitis. Gut 1995, 37:838-839.
28. Regueiro M., Loftus E.V., Steinhart A.H., et al. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006, 12:979-994.
29. Safdi M., DeMicco M., Sninsky C., et al. Adouble-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997, 92:1867-1871.
30. Marshall J.K., Thabane M., Steinhart A.H., et al. Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2010, (1). CD004115.
31. Rao S.S. Diagnosis and management of fecal incontinence. American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2004, 99:1585-1604.
32. Boyle D.J., Knowles C.H., Murphy J., et al. The effects of age and childbirth on anal sphincter function and morphology in 999 symptomatic female patients with colorectal dysfunction. Dis Colon Rectum 2012, 55:286-293.
33. Gisbert J.P., Gonzalez-Lama Y., Mate J. 5-Aminosalicylates and renal function in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2007, 13:629-638.
34. So K., Bewshea C.M., Heap G.A., et al. 5-Aminosalicylate (5-ASA) induced nephrotoxicity in inflammatory bowel disease. Gastroenterology 2013, 144:S112.
35. Thomas T.P. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology 1984, 30:60-65.
36. Akerkar G.A., Peppercorn M.A., Hamel M.B., et al. Corticosteroid-associated complications in elderly Crohn's disease patients. Am J Gastroenterol 1997, 92:461-464.
37. Ananthakrishnan A.N., McGinley E.L., Binion D.G., et al. Fracture-associated hospitalizations in patients with inflammatory bowel disease. Dig Dis Sci 2011, 56:176-182.
38. Bernstein C.N. Osteoporosis and other complications of inflammatory bowel disease. Curr Opin Gastroenterol 2002, 18:428-434.
39. Moscandrew M., Mahadevan U., Kane S. General health maintenance in IBD. Inflamm Bowel Dis 2009, 15:1399-1409.
40. Timmer A., McDonald J.W., Macdonald J.K. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007, (1). CD000478.
41. Prefontaine E., Macdonald J.K., Sutherland L.R. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009, (4). CD000545.
42. Irving P.M., Shanahan F., Rampton D.S. Drug interactions in inflammatory bowel disease. Am J Gastroenterol 2008, 103:207-219.
43. Bermejo F., Gisbert J.P. Usefulness of salicylate and thiopurine coprescription in steroid-dependent ulcerative colitis and withdrawal strategies. Ther Adv Chronic Dis 2010, 1:107-114.
44. Khan N., Abbas A., Lichtenstein G.R., et al. Risk of lymphoma in patients with ulcerative colitis treated with thiopurines - a nationwide retrospective cohort study. Gastroenterology 2013, 10.1053/j.gastro.2013.07.035.
45. Beaugerie L., Brousse N., Bouvier A.M., et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009, 374:1617-1625.
46. Long M.D., Martin C.F., Pipkin C.A., et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012, 143:390-399.
47. Peyrin-Biroulet L., Khosrotehrani K., Carrat F., et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011, 141:1621-1628.
48. Penn I. Evaluation of transplant candidates with pre-existing malignancies. Ann Transplant 1997, 2:14-17.
49. Beaugerie L., Carrat F., Chevaux J.B., et al. Risk of subsequent cancer under immunosuppressive therapy in patients with inflammatory bowel disease and prior cancer: data from the CESAME prospective observational cohort. Gastroenterology 2012, 142:S122.
50. Bernheim O., Colombel J.F., Ullman T.A., et al. The management of immunosuppression in patients with inflammatory bowel disease and cancer. Gut 2013, 62(11):1523-1528. 10.1136/gutjnl-2013-305300.
51. Cottone M., Kohn A., Daperno M., et al. Age is a risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol 2010, 9:30-35.
52. Desai A., Zator Z.A., de Silva P., et al. Older age is associated with higher rate of discontinuation of anti-TNF therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2013, 19(2):309-315. 10.1002/ibd.23026.
53. Tran S., Hooker R.S., Cipher D.J., et al. Patterns of biologic agent use in older males with inflammatory diseases: an institution-focused, observational post-marketing study. Drugs Aging 2009, 26:607-615.
54. Oei H.B., Hooker R.S., Cipher D.J., et al. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009, 27:926-934.
55. Ding T., Ledingham J., Luqmani R., et al. BSR and BHPR rheumatoid arthritis guidelines on safety of anti-TNF therapies. Rheumatology 2010, 49:2217-2219.
56. Chung E.S., Packer M., Lo K.H., et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003, 107:3133-3140.
57. Mann D.L., McMurray J.J., Packer M., et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004, 109:1594-1602.
58. Rennard S.I., Fogarty C., Kelsen S., et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007, 175:926-934.
59. Loftus C.G., Loftus E.V., Harmsen W.S., et al. Update on the incidence and prevalence of Crohn's disease and ulcerative colitis in Olmsted County, Minnesota, 1940-2000. Inflamm Bowel Dis 2007, 13:254-261.
60. Charpentier C., Salleron J., Savoye G., et al. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study. Gut 2013, 10.1136/gutjnl-2012-303864.
61. Ha C.Y., Newberry R.D., Stone C.D., et al. Patients with late-adult-onset ulcerative colitis have better outcomes than those with early onset disease. Clin Gastroenterol Hepatol 2010, 8:682-687.
62. Benchimol E.I., Cook S.F., Erichsen R., et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. JCrohns Colitis 2012, 7(11):878-889. 10.1016/j.crohns.2012.09.001.
63. Juneja M., Baidoo L., Schwartz M.B., et al. Geriatric inflammatory bowel disease: phenotypic presentation, treatment patterns, nutritional status, outcomes, and comorbidity. Dig Dis Sci 2012, 57:2408-2415.
64. Ananthakrishnan A.N., McGinley E.L., Binion D.G. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm Bowel Dis 2009, 15:182-189.
65. Parian A., Ha C. Severe polypharmacy and major medication interactions are associated with increasing age and comorbidity among inflammatory bowel disease patients. Gastroenterology 2013, 144:S11.
66. Cross R.K., Wilson K.T., Binion D.G. Polypharmacy and Crohn's disease. Aliment Pharmacol Ther 2005, 21:1211-1216.
67. American Geriatrics Society 2012 Beers Criteria Update Expert Panel American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. JAm Geriatr Soc 2012, 60:616-631.
68. Katz S., Surawicz C., Pardi D.S. Management of the elderly patients with inflammatory bowel disease: practical considerations. Inflamm Bowel Dis 2013, 19:2257-2272.